Kriya Medical Technologies receives manufacturing license for KRIVIDA Novus RT-PCR kit

The KRIVIDA Novus RT-PCR kit, priced at Rs 150 + taxes, can detect the Omicron variant, its sub-lineages, and the delta variant in 45 minutes

Kriya Medical Technologies, a medical devices company headquartered in Chennai, has received its manufacturing license from the DCGI (Drugs Controller General of India) for its product KRIVIDA Novus, an RT-PCR kit that can detect the Omicron variant and its sub-lineages in 45 minutes. It has been developed in collaboration with ImmuGenix Bioscience. It will be produced at Kriya’s manufacturing facility in Oragadam in Chennai. The company currently has a production capacity of 5 million tests per month and plans to increase it to 10 million tests per month within the next two weeks.

Priced at Rs 150 +taxes, the test is affordable and most suitable for entry point screening at airports. The kit is compatible with Real-Time PCR machines with a test  run time of roughly 45 minutes. It provides early report to aid diagnosis and also gives precise variants to enable appropriate treatment.

KRIVIDA Novus kit can detect COVID-19 and differentiate the other variants from Omicron in single-tube assay.

Anu Moturi, CEO and Founder, Kriya Medical Technologies, said, “I thank the ICMR and DCGI for their swift action. Acquiring this license is yet another milestone and a step towards our vision of making good healthcare affordable and accessible to all. Our focus is to make testing for COVID-19 variants faster, affordable and accessible to everyone, thereby enabling swift prevention and timely treatment. Since KRIVIDA Novus can detect the Omicron variant (B.1.1.529) and all its sub-lineages, such as BA.1, BA.2 and BA.3 in 45 minutes, it is most ideal and beneficial for entry point screening at airports and remobilisation of normal conditions in workplace and institutions.”

The company has a pipeline of new products that will be released in the market over the next few months to address rapidly evolving mutations and other allied infections.